In short
A new drug called VE202, containing live bacterial strains including Clostridia, Cluster XIVa, Strain Relative Eisenbergiella Porci, is being studied in clinical trials for the treatment of mild to moderate ulcerative colitis. This Phase 2 study aims to evaluate the efficacy and safety of VE202 in patients who have not previously received certain types of treatments for their condition.
At a glance
- Study Type
- Phase 2, randomized, double-blind, placebo-controlled
- Condition
- Mild to moderate ulcerative colitis
- Intervention
- VE202 (capsule containing live bacterial strains)
- Primary Endpoints
- Endoscopic response rate at Day 56, safety assessments
- Treatment Duration
- 8 weeks
- Key Inclusion Criteria
- Adults 18-75 years, UC diagnosis for at least 3 months, specific disease activity criteria
- Key Exclusion Criteria
- Prior biologic or JAK inhibitor treatment, recent antibiotic use, active infections
What is VE202?
VE202 is an innovative medication being developed to treat mild to moderate ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum. VE202 is currently undergoing a Phase 2 clinical trial to evaluate its effectiveness and safety for patients with this condition.
How VE202 Works
VE202 is a unique treatment that contains multiple strains of live bacteria. These bacteria belong to various groups, including: Clostridia (Cluster XIVA and Cluster IV) Bacilli (Cluster XVIII) The medication is designed to restore balance to the gut microbiome, which is the community of microorganisms living in our digestive system. In people with ulcerative colitis, this balance is often disrupted.
Potential Benefits of VE202
While the full benefits of VE202 are still being studied, researchers hope that it will: Reduce inflammation in the colon and rectum Improve symptoms of ulcerative colitis, such as diarrhea and rectal bleeding Help heal the lining of the colon Provide a new treatment option for patients who haven't responded well to other therapies It's important to note that these potential benefits are still being investigated in the ongoing clinical trial.
Current Clinical Trial
VE202 is currently being studied in a Phase 2 clinical trial. This trial is: Randomized: Participants are randomly assigned to receive either VE202 or a placebo Double-blind: Neither the participants nor the researchers know who is receiving the actual medication Placebo-controlled: Some participants receive an inactive substance (placebo) to compare results The main goals of this study are: To evaluate how well VE202 works in improving the appearance of the colon lining after 8 weeks of treatment To assess the safety of VE202 Researchers will be looking at whether VE202 can reduce the Mayo endoscopic subscore, which is a measure of how inflamed and damaged the colon lining appears during a medical examination.
Who Can Participate in the Trial?
The clinical trial has specific criteria for who can participate. Some key eligibility factors include: Age: 18 to 75 years old Diagnosis: Confirmed ulcerative colitis for at least 3 months Disease activity: Mild to moderate ulcerative colitis, as determined by specific scoring systems Treatment history: No previous use of certain medications like biologics or JAK inhibitors There are also several exclusion criteria, such as having other digestive conditions or recent use of antibiotics or probiotics.
Safety Considerations
As with any new medication, safety is a top priority in the VE202 clinical trial. The researchers are closely monitoring for any side effects or adverse reactions. Some important safety points include: The trial excludes people with certain medical conditions or those taking specific medications to minimize risks Participants are carefully screened and monitored throughout the study The trial is designed to evaluate both the effectiveness and safety of VE202 It's important to remember that VE202 is still an experimental treatment, and its full safety profile is not yet known.